Grade 3 or worse adverse events seen in more than 5 % of patients were neutropenia ( 203 [ 38 % ] of 529 patients in the ramucirumab group vs 123 [ 23 % ] of 528 in the placebo group , with febrile neutropenia incidence of 18 [ 3 % ] vs 13 [ 2 % ] ) , hypertension ( 59 [ 11 % ] vs 15 [ 3 % ] ) , diarrhoea ( 57 [ 11 % ] vs 51 [ 10 % ] ) , and fatigue ( 61 [ 12 % ] vs 41 [ 8 % ] ) .